PAVM PAVmed (PAVM) Insider Trading, Ownership & Congress Trades
Medical Devices · Surgical & medical instruments & apparatus · CIK 0001624326
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
10
13F, latest reported quarter
PAVM filings, in plain words
Read the full summary
The latest 5% ownership filing is a 13D by Aklog Lishan, filed 2026-04-09, for 5.1% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
PAVmed insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for PAVmed Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Dec 6, 2022.
- -25.8% median (-25.8% mean) 90-day return after 2 previous buys.
- The trade is 40.0% of the 250,000 shares held after it.
- No other insider bought within 30 days.
- 10 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Glennon Michael J bought about $62.0K of PAVM on Dec 7, 2022, the largest insider purchase at the company on our record; 10 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Dec 5, 2022.
- The trade is 58.7% of the 150,000 shares held after it.
- No other insider bought within 30 days.
- 10 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Glennon Michael J bought about $56.3K of PAVM on Dec 6, 2022, the largest insider purchase at the company on our record; 10 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 62,000 shares held after it.
- No other insider bought within 30 days.
- 10 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Glennon Michael J bought about $42.8K of PAVM on Dec 5, 2022, the largest insider purchase at the company on our record; 10 funds added in the latest 13F quarter.3 transactions on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
10 funds bought in last quarter
below 85% of Medical Devices
Revenue
-97.6% year over year
below 98% of Medical Devices
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
0.3% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
below 85% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch PAVM
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-82.4%12M
13D/G stake
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns PAVM: institutional holders (13F)
13F holdings, latest reported quarter
461,539 sh
$2.7M
332,911 sh
$2.0M
61,604 sh
$365.9K
36,678 sh
$217.9K
25,605 sh
$152.1K
Congress trades in PAVM
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
13D: intends to influence · 13G: passive
Aklog Lishan
Activist 13D · 2026-04-09
5.1%
PAVM planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
PAVM mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
iShares Micro-Cap ETF
$81.9K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$5.2K position · as of 2026-06-30
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$343.8K position · as of 2026-06-30
0.0%
Total Stock Market Index Trust
$1.3K position · as of 2026-06-30
0.0%
Fidelity Extended Market Index Fund
$38.2K position · as of 2026-05-31
0.0%
Fidelity Series Total Market Index Fund
$7.5K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Lishan Aklog, M.D
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$1.0M
$992.5K
$595.8K
-97%
n/a
2024
$1.4M
$798.3K
$1.1M
-98%
n/a
2023
$953.2K
$882.5K
$627.3K
-89%
n/a
2022
$1.6M
-$2.0M
$1.3M
-80%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 10 funds added last quarter. Each figure is a federal filing, dated the day it went public.
PAVM financials
Revenue growth
-97.6%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$112.0K
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM PAVM
| FY Dec 2025 | $71.0K |
| FY Dec 2024 | $3.0M |
| FY Dec 2023 | $2.5M |
| FY Dec 2022 | $377.0K |
| FY Dec 2021 | n/a |
| Jun 2026 | $33.0K |
| Mar 2026 | $22.0K |
| Dec 2025 | $52.0K |
| Sep 2025 | $5.0K |
| Jun 2025 | $6.0K |
| Mar 2025 | $8.0K |
| Dec 2024 | $0 |
| Sep 2024 | $1.0M |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Net margin, TTM PAVM
| FY Dec 2025 | n/a |
| FY Dec 2024 | +1,062% |
| FY Dec 2023 | -2,651% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | +6,440% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$7.8M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM PAVM
| FY Dec 2025 | -$5.2M |
| FY Dec 2024 | -$33.6M |
| FY Dec 2023 | -$52.3M |
| FY Dec 2022 | -$72.5M |
| FY Dec 2021 | -$42.1M |
| Jun 2026 | -$2.7M |
| Mar 2026 | -$2.6M |
| Dec 2025 | -$1.6M |
| Sep 2025 | -$899.0K |
| Jun 2025 | -$1.2M |
| Mar 2025 | -$1.6M |
| Dec 2024 | $90.0K |
| Sep 2024 | -$8.9M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity PAVM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt PAVM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-44.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity PAVM
| FY Dec 2025 | -24.0% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -342.3% |
| FY Dec 2021 | -158.4% |
| Jun 2026 | -44.8% |
| Mar 2026 | -54.0% |
| Dec 2025 | -24.0% |
| Sep 2025 | -34.2% |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-38.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets PAVM
| FY Dec 2025 | -10.9% |
| FY Dec 2024 | +100.2% |
| FY Dec 2023 | -152.2% |
| FY Dec 2022 | -126.3% |
| FY Dec 2021 | -94.3% |
| Jun 2026 | -38.7% |
| Mar 2026 | -46.4% |
| Dec 2025 | -10.9% |
| Sep 2025 | -13.8% |
| Jun 2025 | +156.2% |
| Mar 2025 | +146.9% |
| Dec 2024 | +100.2% |
| Sep 2024 | +61.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital PAVM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-76.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed PAVM
| FY Dec 2025 | -227.3% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -197.6% |
| FY Dec 2021 | -118.7% |
| Jun 2026 | -76.8% |
| Mar 2026 | -57.5% |
| Dec 2025 | -227.3% |
| Sep 2025 | -196.0% |
| Jun 2025 | -277.4% |
| Mar 2025 | -284.0% |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing PAVM
| FY Dec 2025 | n/a |
| FY Dec 2024 | 1.60x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | 7.03x |
| Jun 2025 | 5.04x |
| Mar 2025 | 0.88x |
| Dec 2024 | 1.60x |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value PAVM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-43.1%
TTM free cash flow over market value at close 2026-10-26
FCF yield PAVM
| FY Dec 2025 | -4.7% |
| FY Dec 2024 | -15.5% |
| FY Dec 2023 | -0.4% |
| FY Dec 2022 | -0.4% |
| FY Dec 2021 | -0.0% |
| Jun 2026 | -18.0% |
| Mar 2026 | -9.7% |
| Dec 2025 | -4.7% |
| Sep 2025 | -1.7% |
| Jun 2025 | -3.8% |
| Mar 2025 | -6.1% |
| Dec 2024 | -15.5% |
| Sep 2024 | -11.3% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing PAVM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $71.0K | $3.0M | $2.5M | $377.0K |
| Operating income | -$21.8M | -$44.5M | -$68.8M | -$91.1M |
| Net income | -$3.8M | $32.0M | -$66.3M | -$89.0M |
| EPS (diluted) | -5.63 | 14.90 | -9.16 | -15.03 |
| Operating cash flow | -$5.2M | -$33.6M | -$52.0M | -$71.0M |
| Cash | $1.5M | $1.2M | $19.6M | $39.7M |
SEC XBRL, fiscal years, as known on 2026-10-28
PAVM Stock Sonar score 4/7 axes
Find similar shapesComparePAVM ranks highest on risk and compliance (80th percentile) and profitability (33rd), and lowest on growth (2nd), among Medical Devices peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
